 |
lentiviral transfected chimeric antigen receptor T-cells modified to target B-cell maturation antigen and CS1 |
|---|---|
| Trade Name | not avaiable |
| Orphan Indication | 1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole |
| USA Market Approval | USA |
| USA Designation Date | 2018-01-09 00:00:00 |
| Sponsor | iCell Gene Therapeutics 25 Health Sciences Drive, Suite 118 Stony Brook, New York, 11793 |
